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26 Abstract
27 The corticotropin releasing hormone (CRH) family of peptides, including urocortin (UCN) 1, 
28 2 and 3, are established hypothalamic neuroendocrine peptides, regulating the physiological 
29 and behaviour responses to stress indirectly, via the hypothalamic-pituitary-adrenal (HPA) 
30 axis. More recently, these peptides have been implicated in diverse roles in peripheral organs 
31 through direct signalling, including in placental and pancreatic islet physiology. CRH has 
32 been shown to stimulate insulin release through activation of its cognate receptors, CRH 
33 receptor 1 (CRHR1) and 2. However, the physiological significance of this is unknown. We 
34 have previously reported that during mouse pregnancy, expression of CRH peptides increase 
35 in mouse placenta suggesting that these peptides may play a role in various biological 
36 functions associated with pregnancy, particularly the pancreatic islet adaptations that occur in 
37 the pregnant state to compensate for the physiological increase in maternal insulin resistance. 
38 In the current study, we show that mouse pregnancy is associated with increased circulating 
39 levels of UCN2 and that when we pharmacologically block endogenous CRHR signalling in 
40 pregnant mice, impairment of glucose tolerance is observed. This effect on glucose tolerance 
41 was comparable to that displayed with specific CRHR2 blockade and not with specific 
42 CRHR1 blockade. No effects on insulin sensitivity or the proliferative capacity of β-cells 
43 were detected. Thus, CRHR2 signalling appears to be involved in β-cell adaptive responses to 
44 pregnancy in the mouse, with endogenous placental UCN2 being the likely signal mediating 
45 this. 
46
47
48
49
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51
52 Introduction 
53 The corticotropin releasing hormone (CRH) peptide family comprises CRH and the 
54 structurally related urocortin peptides (UCN1, UCN2 and UCN3).  These  neuroendocrine 
55 peptides are best known for their involvement in regulating the physiological and behavioural 
56 responses to stress, through the cognate G-protein coupled receptors (GPCRs), CRH receptor 
57 1 (CRHR1) and CRH receptor 2 (CRHR2) (Bakshi et al., 2002; Chen et al., 1993; Lovenberg 
58 et al., 1995; Weninger et al., 1999), as part of the hypothalamic-pituitary-adrenal (HPA) axis. 
59 More recent evidence suggests additional, diverse, extra-hypothalamic roles for these 
60 peptides in peripheral organs (Chatoo et al., 2018; Chatzaki et al., 2019; Paschos et al., 2013). 
61 Thus, CRH expression has been reported in the adrenal gland and the gastrointestinal tract 
62 (Suda et al., 1984); UCN1 is expressed in heart, skin and adipose tissue (Kimura et al., 2002; 
63 Seres et al., 2004; Wierzbicka et al., 2017); and UCN2 and UCN3 have been detected in 
64 peripheral blood cells, skeletal muscle, pancreas and gestational tissues such as fetal 
65 membranes and placental villi (Petraglia et al., 2010). CRHR1 and CRHR2 are also 
66 expressed in a wide range of tissues, including cardiac myocytes, the adrenal gland, adipose 
67 tissue,  skeletal muscle and skin (Hillhouse and Grammatopoulos, 2001), also suggesting 
68 physiological roles for the CRH peptide family unrelated to the HPA axis. However, under 
69 normal circumstances, levels of the peptides in the peripheral circulation are low (Ng et al., 
70 2004; Sasaki et al., 1987), suggesting that the peptides may be produced locally to function as 
71 autocrine or paracrine agents in tissues where the respective receptors are also expressed (Li 
72 et al., 2013; van der Meulen et al., 2015; Zouboulis et al., 2002). 
73
74 There is increasing evidence that the CRH peptide family may be involved in peripheral 
75 metabolic control via direct actions on insulin-secreting β-cells in pancreatic islets of 
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76 Langerhans (Li et al., 2007; Schmid et al., 2011). Both CRHR1 and CRHR2 are expressed in 
77 rodent (Kanno et al., 1999; Schmid et al., 2011) and human islets (Amisten et al., 2013), 
78 whilst in vitro administration of exogenous CRH stimulates insulin secretion from mouse and 
79 human islets as well as enhancing proliferation in neonatal rat β-cells (Huising et al., 2010). 
80 Similarly, β-cell derived UCN3 has been implicated in the local regulation of both insulin and 
81 glucagon release (Li et al., 2007). Despite the evidence demonstrating direct effects of 
82 exogenous CRH on islet function, the physiological relevance of this interaction is unclear, 
83 given the islets would not normally be exposed to significant levels of peptides of the CRH 
84 family. There is some evidence that placentally-derived CRH and urocortins are involved in 
85 various biological functions associated with pregnancy (Thomson, 2013; You et al., 2014). 
86 Thus, pregnancy represents one possible physiological state in which the effects of the CRH 
87 family on islet function may play a role. 
88
89 During pregnancy, maternal insulin resistance increases and this is compensated for by 
90 increases in β-cell mass and enhanced insulin secretory responses to elevations in plasma 
91 glucose (Baeyens et al., 2016; Pasek and Gannon, 2013; Xue et al., 2010). We have recently 
92 reported an upregulation of CRH, UCN2 and UCN3 mRNA expression in mouse placenta on 
93 gestational day 12 (Drynda et al., 2018), which correlates to the initiation of  β-cell 
94 adaptations in rodent pregnancy (Rieck and Kaestner, 2010). Similarly, in human pregnancy, 
95 levels of CRH in the peripheral circulation increase as gestation progresses (Campbell et al., 
96 1987; Sasaki et al., 1987) and CRH immunoreactivity has been reported in human placenta 
97 (Grino et al., 1987), consistent with a placental source for the circulating CRH. In the current 
98 study, we have therefore investigated a potential role for the CRH peptide family in the 
99 regulation of glucose homeostasis during pregnancy.
100
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101
102 Materials and methods 
103 Animals 
104 Female Institute of Cancer Research (ICR) mice (8-12 weeks of age, Envigo, Bicester, UK) 
105 were used for in vivo studies. This is a commonly used outbred mouse strain with very good 
106 reproductive and maternal characteristics. All animals were housed under controlled, 
107 pathogen free conditions (12-hour light/ dark cycle (0700 – 1900 hr lights on), temperature 
108 22±2oC) and provided with standard chow diet and water ad libitum. For timed pregnancy 
109 studies, female mice were mated with male ICR mice and the presence of vaginal plug 
110 assessed daily and denoted day 1 of pregnancy if present. Age-matched female mice were 
111 used for non-pregnant studies, with procedures carried out at the same time intervals as 
112 described for pregnancy studies. All procedures were conducted under approval by King’s 
113 College London Animal Welfare and Ethical Review Board and were undertaken in 
114 accordance with United Kingdom Home Office Regulations.  
115
116 Islet isolation and insulin secretion in vitro 
117 For in vitro insulin secretion studies, pancreatic islets were isolated from female ICR mice 
118 via collagenase digestion of the exocrine pancreas, as described previously (Rackham et al., 
119 2016). Isolated islets were subsequently maintained at 37oC in RPMI (Sigma, UK) 
120 supplemented with 10% [vol./vol.] fetal bovine serum, 2 mmol/l glutamine and 100 U/ml 
121 penicillin/0.1 mg/ml streptomycin for 24 hours before use. Islets were loaded into a multi-
122 channel, temperature controlled perifusion system, as described previously (Liu et al., 2013), 
123 and pre-perifused  for 1 hour with physiological salt buffer (Bowe et al., 2019) containing 2 
124 mmol/l glucose before being exposed to 20 mmol/l glucose in the presence or absence of the 
125 CRHR agonists,  CRH (50 nmol/l, Sigma, UK), Stressin I (100 nmol/l, Tocris, UK) or UCN2 
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126 (100 nmol/l, Sigma, UK) at 37oC. Perifusate samples were collected every 2 minutes and 
127 insulin secretion was quantified using an in-house insulin radioimmunoassay (Jones et al., 
128 1988). 
129
130 In vivo osmotic minipump studies 
131 Osmotic minipumps (ALZET®, Model 1002, Charles River, UK) were implanted 
132 subcutaneously into pregnant or non-pregnant mice to chronically administer test agents. 
133 Surgical implantation of osmotic minipumps was carried out on day 7 of pregnancy (or 
134 equivalent time interval for non-pregnant mice) under isoflurane anaesthesia (Isothesia®, 
135 Henry Schein®). Minipumps were loaded with physiological saline, non-specific CRHR 
136 antagonist (α-helical CRF9-41, 1 mg/ml, Tocris, UK) or receptor specific CRHR antagonists, 
137 Antalarmin hydrochloride (1 mg/ml, Tocris, UK) or Antisauvagine-30 (3 mg/ml, Tocris, UK) 
138 for CRHR1 and R2, respectively. Test agents were delivered at a rate of 0.25 µl /hour for a 
139 total period of 11 days. Assessment of glucose tolerance and insulin tolerance were 
140 conducted on gestational days 16 and 18, respectively. 
141
142 Assessment of glucose homeostasis 
143 Intraperitoneal glucose tolerance tests (IPGTT) were conducted on day 16 of gestation. Mice 
144 were fasted from 0900 for 6 hours and then administered with glucose (2 g/kg, Sigma, UK). 
145 Blood sampling was performed by small tail prick at time points 0, 15, 30, 60, 90 and 120 
146 min following glucose administration to determine blood glucose levels using an Accu-Chek 
147 glucose meter (Roche Diagnostics, UK).  Intraperitoneal insulin tolerance tests (IPITT) were 
148 conducted on day 18 of gestation. Mice were again fasted from 0900 for 6 hours prior to 
149 metabolic testing and were subsequently administered with insulin (0.75 IU/kg, Sigma, UK). 
Page 6 of 32Accepted Manuscript published as JOE-19-0568.R1. Accepted for publication: 27-Feb-2020
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 03/02/2020 12:14:38PM
via King's College London, King's College London, Kings College London, Kings College London and Kings College London
150 Blood sampling was performed by small tail prick at time points 0, 15, 30, 45 and 60 min 
151 following insulin injection to determine blood glucose levels.
152 Measurements of circulating CRH-related peptides
153 On day 18, animals were euthanised by intraperitoneal injection of terminal anaesthesia 
154 (Euthatal®, Merial Animal Health Ltd, UK) and terminal blood samples were collected via 
155 cardiac puncture into sterile heparin-coated tubes. Samples were also collected from control 
156 pregnant mice on day 16.  Samples were centrifuged (1,800 rcf, 20 minutes, 4oC) and the 
157 subsequent plasma stored at -20°C for later assay of circulating peptide levels using 
158 commercially available ELISA kits (CRH: CEA835Mu, Cloud-Clone Corp, USA; UCN1: 
159 CEA231Mu, Cloud-Clone Corp, USA; UCN2: MOFI00425, ELISAGenie, UK; UCN3: 
160 CED140Mu, Cloud-Clone Corp, USA) following the manufacturers’ instructions.
161
162 Quantification of mRNA expression
163 Isolated female islets from non-pregnant and pregnant (day 16) mice were immediately snap 
164 frozen in liquid nitrogen following purification from the exocrine pancreas for subsequent 
165 RNA extraction using RNeasy Mini Kit (Qiagen, UK) and High Capacity cDNA Reverse 
166 Transcription Kit (Applied BiosystemsTM, UK) for cDNA synthesis, as described previously 
167 (Drynda et al., 2018). Placenta samples were also collected after termination at day 18 of 
168 pregnancy and snap frozen. RNA extraction and cDNA conversion were conducted as 
169 described above. Islet CRH receptor and placental CRH ligand mRNA expression was 
170 subsequently quantified by quantitative reverse transcription polymerase chain reaction 
171 (qRT-PCR) using SYBR Green PCR Kit (QuantiTect, Qiagen, UK) and a LC96 Light Cycler 
172 (Roche Diagnostics, UK).  QuantiTect primer assays were used for expression analysis of 
173 genes of interest using Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) as the 
174 housekeeping gene (Mouse Crh- QT01055789, Ucn1- QT00326879, Ucn2-QT01556534, 
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175 Ucn3-QT00302267, Crhr1-QT00106232, Crhr2-QT00151543, Gapdh-QT01658692, Qiagen, 
176 UK).  
177
178 Assessment of β-cell mass 
179 For osmotic minipump studies, bromo-deoxy-uridine (BrdU, 1 mg/ml, Sigma, UK) was 
180 administered in the drinking water from day 14 to day 18 of pregnancy with fresh BrdU 
181 drinking water being replaced every two days. After termination at day 18, pancreata were 
182 dissected, fixed in 4% paraformaldehyde (Sigma, UK) and embedded in paraffin wax before 
183 being cut into 5µm thick sections using Leica microtome (RM2255).  Representative sections 
184 (3-4 sections per animal), approximately 150 µm apart, were co-stained with guinea pig anti-
185 insulin antibody (1:200, Dako, UK) to visualise islet β-cells and monoclonal mouse anti-
186 BrdU antibody (1:100, Sigma, UK) to identify proliferating cells as previously described 
187 (Bowe et al., 2019). Images were taken on Nikon Eclipse TE2000-U fluorescent microscope 
188 and quantification of BrdU positive β-cells and β-cell area was performed using ImageJ 1.49c 
189 software.  
190
191 Statistical analysis 
192 Statistical analysis was performed using GraphPad Prism 8.0 software. For comparison 
193 between two groups, unpaired, two-tailed students t-test was used. For in vivo glucose and 
194 insulin tolerance tests, two-way repeated measures ANOVA was used, followed by Tukey’s 
195 multiple comparison test to identify significance between multiple groups. 
196
197
198 Results 
199 CRH receptor gene expression profile in pregnancy 
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200 Islets isolated from non-pregnant and pregnant (d.16) female mice expressed both Crhr1 and 
201 Crhr2 mRNAs, as shown in Figure 1. As expected, Crhr1 expression in islets was higher 
202 than Crhr2 expression, displaying an analogous expression pattern for the receptors to that in 
203 the pituitary, a classical target for CRH.  Islet Crhr1 mRNA expression was significantly 
204 reduced during pregnancy compared to non-pregnant levels (Fig. 1A), whereas islet Crhr2 
205 mRNA levels were unchanged between non-pregnant and pregnant animals (Fig. 2B). Thus, 
206 islets express receptors for the entire CRH family of peptides.
207
208 Effects of CRH receptor stimulation on insulin secretion
209 Activating either CRHR1 or CRHR2 enhanced glucose-induced insulin secretion from 
210 isolated mouse islets in a dynamic perifusion system, as shown in Figure 2. Exposure to 20 
211 mmol/l glucose initiated a rapid increase in insulin secretion, which was further potentiated 
212 by the addition of CRH (acting as a non-specific CRHR1 and CRHR2 agonist, Fig. 2A); 
213 Stressin I (a CRHR1 specific agonist, Fig. 2C); or of UCN2 (a CRHR2 specific agonist, Fig. 
214 2E). Area under the curve quantification of glucose stimulated insulin secretion (30-50 min) 
215 confirms the significant potentiation of insulin secretion in the presence of stimulatory 
216 concentrations of glucose, induced by all CRH receptor agonists tested (Fig. 2B, D, F). 
217 CRHR agonists had no significant effect on insulin secretion at a sub-stimulatory 
218 concentration of glucose (Data not shown, 2 mmol/l glucose: Control: 0.056 ± 0.010 
219 ng/islet/hr vs + 50 nmol/l CRH: 0.045 ± 0.009 vs + 100 nmol/l Stressin I: 0.034 ±  0.007 vs + 
220 100 nmol/l Ucn2: 0.053 ± 0.008, mean ± SEM, n=9 observations p>0.999). Thus, activation 
221 of CRHR1 or CRHR2 potentiates glucose-stimulated insulin secretion from islet β-cells.
222
223 Circulating CRH and urocortin profile during pregnancy 
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224 qRT-PCR measurements demonstrated that mRNAs for Crh, Ucn1, Ucn2 and Ucn3 were all 
225 expressed by mouse placenta at day 18 at similar levels (Fig. 3A), confirming our previous 
226 observations (Drynda et al., 2018).  Furthermore, all four peptides were detected in the 
227 peripheral circulation, with UCN2 being the most abundant circulating CRHR agonist (Fig. 
228 3B). The circulating levels of CRH, UCN1 and UCN3 were unchanged between non-
229 pregnant and pregnant female mice. However, circulating levels of UCN2 were elevated 
230 almost 2-fold by day 16 of pregnancy when compared to age-matched virgin female controls 
231 (Fig. 3B). Thus, the pancreatic islets are likely to be exposed to elevated levels of UCN2 
232 during pregnancy, with the placenta being the most likely source for the increased levels. 
233 Therefore, the candidate ligand of the CRH family to play a physiological role in the islet 
234 adaptation to pregnancy appears to be UCN2.  
235
236 Effect of pharmacologically blocking endogenous CRH receptor signalling during 
237 pregnancy
238 The consequences of pharmacological blockade of CRH receptor signalling in vivo was 
239 assessed in both non-pregnant and pregnant mice, revealing a pregnancy- and receptor- 
240 specific phenotype, as shown in Figure 4.  As expected, intraperitoneal administration of 
241 glucose, elevated blood glucose levels within 15 minutes in both pregnant and non-pregnant 
242 mice (Fig. 4A, E). Chronic pharmacological blockade of total CRHR signalling during 
243 pregnancy with a non-selective antagonist, α-helical CRF9-41, resulted in a mild impairment to 
244 glucose tolerance, with significantly higher blood glucose concentrations at 15 minutes after 
245 glucose administration, compared to saline controls (Fig. 4A). Chronic administration of the 
246 CRHR2 antagonist, Antisauvagine-30, resulted in a similar impairment to glucose tolerance 
247 in pregnant mice, but not in animals treated with the specific CRHR1 antagonist, Antalarmin 
248 hydrochloride (Fig. 4A, B). These data are consistent with an endogenous ligand, acting via 
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249 CRHR2, playing a physiological role in maintaining normal glucose tolerance during 
250 pregnancy. All pregnant mice were insulin resistant by day 18 of pregnancy as indicated by 
251 the failure to respond to exogenous insulin administration and lowering of blood glucose, 
252 however, none of the CRHR antagonists had any detectable effects on insulin sensitivity (Fig. 
253 4C, D). Chronic treatment of non-pregnant female mice with α-helical CRF9-41 to block total 
254 CRHR signalling had no significant effect on glucose tolerance or insulin sensitivity (Fig. 
255 4E-H). Given the lack of effect of α-helical CRF9-41, receptor specific antagonists were not 
256 tested outside of pregnancy. Thus, CRHR2 activation by an endogenous ligand is involved in 
257 maintaining glucose homeostasis specifically during pregnancy.
258
259 In addition to effects on whole body glucose homeostasis, pregnancy in mice is also 
260 associated with an increased rate of β-cell proliferation to increase the functional β-cell mass 
261 (Rieck and Kaestner, 2010). This was evaluated by BrdU+ β-cell staining (Fig. 5A, B). 
262 Chronic blockade of total CRHR signalling during pregnancy using α-helical CRH9-41, had no 
263 significant effects on β-cell proliferation, β-cell size or the average insulin+ β-cell area, as 
264 shown in Figure 5C-E. The effects of CRHR activation on glucose homeostasis during 
265 pregnancy are therefore most likely direct effects on the β-cell to enhance insulin secretion 
266 rather than to increase the β-cell mass.    
267
268
269 Discussion  
270 During pregnancy, the metabolic profile of the mother adapts to ensure a sufficient supply of 
271 energy for the developing fetus. A progressive increase in maternal insulin resistance across 
272 pregnancy represents a key mechanism for increasing fuel availability to the fetus (Freemark, 
273 2006; Newbern and Freemark, 2011). This insulin resistance is compensated for by an 
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274 increase in the maternal functional β-cell mass and enhanced insulin secretory responses 
275 (Baeyens et al., 2016). Failure of the β-cell to adapt to the maternal metabolic load can lead 
276 to maternal glucose intolerance and, eventually, to overt gestational diabetes (Plows et al., 
277 2018; Zhang et al., 2010). In rodent models, the early β-cell adaptations to pregnancy involve 
278 non-placental signals (Drynda et al., 2015), but as placentation is established and pregnancy 
279 progresses, the placenta becomes an important endocrine organ, secreting numerous 
280 hormonal signals, which influence maternal and fetal physiology (Jansson, 2016). The 
281 lactogenic hormones, prolactin and placental lactogen, are important pregnancy associated 
282 signals, well-established to act  via  β-cell prolactin receptors to induce  β-cell mass 
283 expansion and enhance insulin secretion (Brelje et al., 1993; Huang et al., 2009; Sorenson et 
284 al., 1993; Vasavada et al., 2000). These effects may be mediated, at least in part, by an 
285 upregulation of intra-islet serotonin  (Kim et al., 2010; Ohara-Imaizumi et al., 2013). 
286 However, the mouse placenta expresses approximately 80 different ligands for which β-cells 
287 express the cognate GPCRs (Drynda et al., 2018) and it is unlikely that the lactogenic 
288 hormones are the only signals involved in regulating islet adaptations. These placental 
289 ligands include a number of peptides more usually associated with hypothalamic 
290 neuroendocrine functions. We have recently identified kisspeptin as an important placental 
291 signal regulating β-cell function during pregnancy (Bowe et al., 2019). The current study 
292 extends these observations to implicate another classical hypothalamic neuroendocrine 
293 system, the CRH peptide family, in placental control of β-cell function. 
294
295 The expression profile of CRH receptors in mouse islets is consistent with previous reports 
296 confirming the expression of both Crhr1 and Crhr2 using mouse (Huising et al., 2011) or 
297 human (Amisten et al., 2013) islets. These observations suggest that islet cells have an innate 
298 capacity to recognise and respond to circulating CRH and the urocortin peptides. The 
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299 decreased expression levels of Crhr1 during pregnancy is also suggestive of a shift in the 
300 receptor ratio to potentially direct Crhr2 signalling under the influence of placental signals. 
301 Accordingly, our in vitro measurements of insulin secretion from isolated islets, 
302 demonstrated that activation of either CRHR1 or CRHR2 significantly potentiates glucose-
303 stimulated insulin secretion (GSIS). Similar to other β-cell GPCRs, activation of CRHR1 and 
304 CRHR2 only enhanced insulin secretion in the presence of a stimulatory concentration of 
305 glucose, suggesting that the physiological function of receptor activation is to module the 
306 extent of the insulin secretory response to elevated glucose concentrations, rather than to 
307 initiate secretion. Our dynamic measurements of insulin secretion from isolated islets 
308 correspond with studies using mouse or human islets in static incubations (Huising et al., 
309 2010; O’Carroll et al., 2008) and imply that increased levels of CRHR agonists will result in 
310 an enhanced glucose-induced insulin secretory response. However, whilst previous studies 
311 have suggested a role for the CRH family in regulating islet function, the physiological 
312 purpose of this effect was unclear. 
313
314 Placental expression and secretion of CRHR agonists is contentious. Earlier studies detected 
315 CRH mRNA and immunoreactivity in placentae from humans and non-human primates (Frim 
316 et al., 1988; Robinson et al., 1989; Sasaki et al., 1987), but failed to detect it in non-primate 
317 species including  lemur, guinea pig and rat  (Robinson et al., 1989).   In human pregnancy,  
318 levels of CRH in the peripheral circulation  increase as gestation progresses (Campbell et al., 
319 1987; Sasaki et al., 1987). It has thus been suggested that the physiological purpose of this 
320 increase is in regulating parturition through modulation of signals controlling myometrium 
321 contractility and inflammation (McLean et al., 1995; Thomson, 2013; You et al., 2014). 
322 Contrary to human pregnancy, placental CRH in rodents is not thought to have a significant 
323 role in initiating parturition, with evidence of a more influential role in facilitating 
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324 implantation particularly during murine pregnancy (Athanassakis et al., 1999). Increased 
325 expression of  UCN2 mRNA and protein has  been reported in both human and mouse  
326 gestational  tissues (including fetal membranes, myometrium and placenta) (Voltolini et al., 
327 2015), although conflicting reports suggest no significant change in circulating levels of 
328 UCN1, UCN2 or UCN3 during human pregnancy (Pepels et al., 2010). In the current study 
329 we detected the expression of mRNAs for all members of the CRH family in mouse placenta. 
330 Circulating levels of CRH, UCN1 and UCN3 were unchanged in pregnant and non-pregnant 
331 mice, suggesting that these ligands are not released by the mouse placenta at significant 
332 levels, however circulating levels of UCN2 were significantly increased during gestation. The 
333 circulating concentrations of UCN2 which we detected during pregnancy are close to the 
334 reported EC50 values for CRHR2 (Dautzenberg et al., 2004; Hauger et al., 2003; Patel et al., 
335 2012) and are consistent with β-cell CRHR2 activation in response to pregnancy signals. 
336 These observations are also consistent with the placenta being the source of the increased 
337 circulating UCN2 during mouse pregnancy, analogous to the increases in placentally derived 
338 kisspeptin in the circulation during mouse and human pregnancy (Bowe et al., 2019; Dhillo et 
339 al., 2006; Mark et al., 2013), and suggest that it may potentially play a physiological role 
340 during pregnancy. However, it cannot be ruled out that the pregnancy-associated UCN2 
341 derives from an alternative peripheral source, such as skin or skeletal muscle where it is also 
342 highly expressed (Chen et al., 2004).  
343
344 Irrespective of its source, our in vivo studies suggest a role for circulating UCN2 in the 
345 regulation of β-cell insulin secretory responses during mouse pregnancy. Thus, 
346 pharmacological blockade of CRHR2 impaired glucose tolerance in pregnant mice, but a 
347 similar impairment was not observed with CRHR1 blockade, nor in non-pregnant females.  
348 The lack of effect of in vivo CRHR blockade on insulin resistance during pregnancy suggests 
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349 that the impaired glucose tolerance reflects a β-cell targeted effect, consistent with our in 
350 vitro observations of enhanced insulin secretion in response to CRHR2 activation.  Most 
351 placental hormones involved in β-cell adaptations to pregnancy exert dual effects to acutely 
352 increase the rate of insulin secretion from individual β-cells, and chronically to induce 
353 expansion of the functional β-cell pool. These compensatory mechanisms ensure that the 
354 mother can sustain a robust insulin secretory response to elevated plasma glucose, especially 
355 in the prevailing insulin resistant environment. Under normal circumstances the rate of β-cell 
356 proliferation is very low, but chronic exposure to lactogenic hormones (Baeyens et al., 2016; 
357 Brelje et al., 1993; Huang et al., 2009) or to kisspeptin (Bowe et al., 2019) during gestation 
358 increases the rate of β-cell proliferation, and so increases the functional β-cell mass both in 
359 vitro and in vivo.  In the current study, chronic blockade of total CRH receptors during 
360 pregnancy had no significant effects on β-cell size or proliferation, nor on the overall β-cell 
361 mass. This provides further evidence that the impairment to glucose tolerance in vivo during 
362 pregnancy, is due to an endogenous ligand, specifically targeting CRHR2, enhancing β-cell 
363 insulin secretion. The physiological significance of these differences in modes of action of 
364 placental factors is uncertain, but there may be therapeutic advantages in the ability of UCN2 
365 to enhance glucose-induced insulin secretion without targeting the clinical challenges of 
366 manipulating β-cell proliferation. 
367
368 The variability of maternal glycaemia throughout pregnancy can range from normal/mild 
369 glucose intolerance, to severe in the case of gestational diabetes. The pharmacological 
370 blockade of CRHR2 signalling during pregnancy appears to reveal a transient and mild 
371 glucose intolerance in comparison to the more profound defect in glucose tolerance displayed 
372 by mutant PRLR mice (Huang et al., 2009). Given the importance of maintaining appropriate 
373 maternal glycaemic control during pregnancy, it is perhaps not surprising that there are 
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374 multiple control mechanisms that ensure an integrated β-cell insulin secretory response. 
375 Therefore, the mild phenotype displayed may have been compensated by complementary 
376 signals to prevent major disruptions to glucose homeostasis. 
377
378 In summary, we have demonstrated that CRHR2 signalling is involved in β-cell adaptive 
379 responses to pregnancy in the mouse, with endogenous placental UCN2 being the likely 
380 signal mediating this adaptation. Unlike other identified placental signals, the effects of 
381 UCN2 appear to be confined to amplifying glucose-induced insulin secretion without 
382 concomitant alterations in the β-cell mass. Blocking the endogenous CRHR2 agonist during 
383 gestation induces a mild glucose intolerance rather than overt gestational diabetes suggesting 
384 that UCN2 may act in concert with other placental signals to fine-tune the compensatory β-
385 cell adaptations to maternal insulin resistance during pregnancy. Deciphering the interplay 
386 between these different signals will lead to a more comprehensive understanding of the 
387 pathophysiology of gestational diabetes and may offer novel diagnostic or therapeutic 
388 strategies. 
389
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610 Figure legends 
611
612 Figure. 1: Expression of Crhr1 (A) and Crhr2 (B) mRNAs by isolated female islets in non-
613 pregnancy (white bar) and pregnancy day 16 (PD.16; black bar). Anterior pituitary was used 
614 as a positive control (grey bar) and mRNA expression levels were quantified to the relative 
615 expression of housekeeping gene, Gapdh. Crhr1 mRNA expression levels decreased 
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616 significantly during pregnancy (~60%) whereas levels of Crhr2 expression were unchanged. 
617 Data are presented as mean + S.E.M., n=5, *p<0.05; Students T-test non-pregnant vs PD.16.
618 Figure. 2: Effect of exogenous CRH (A), CRHR1 specific agonist Stressin 1 (C) and 
619 CRHR2 specific agonist UCN2 (E) on dynamic insulin secretion from isolated, perifused 
620 female mouse islets. Islets were exposed to physiological buffer containing 20 mmol/l 
621 glucose only or supplemented with agonists between 30-50 mins.  All CRHR agonists 
622 potentiated glucose-stimulated insulin secretion over that seen from control islets, as 
623 demonstrated by the rate of insulin secretion (A,C,E) and area under curve data (B,D,F). 
624 Data are presented as mean ± S.E.M., n= 3-4 per treatment group, AUC 20 mmol/l glucose + 
625 agonist, 30-50 min, *p<0.05, **p<0.01, ***p<0.001; Students T-test control vs agonist 
626 treatment.
627
628 Figure. 3: Expression of CRH and urocortins mRNAs in mouse placenta on day 18 of 
629 pregnancy (PD.18) (A) and circulating concentrations of CRH peptides during mouse 
630 pregnancy (PD.16) (B). Expression levels were quantified to the relative expression of 
631 housekeeping gene Gapdh. Crh, Ucn1, Ucn2 and Ucn3 mRNAs were all expressed by mouse 
632 placenta. Plasma levels of CRH, UCN1 and UCN3 were similar in pregnant and non-
633 pregnant mice. However, plasma UCN2 was significantly elevated during pregnancy. Data 
634 presented as mean + S.E.M., n=6, ***p<0.001; Two-way ANOVA followed by Tukey’s 
635 multiple comparisons test. 
636
637 Figure. 4: Effects of chronic administration of CRHR antagonists on glucose homeostasis 
638 during pregnancy (A-D) and non-pregnancy (E-H). Pregnant mice (PD.16) treated with either 
639 α-helical CRF9-41 or AS-30 (Antisauvagine-30) displayed a significant impairment in glucose 
640 tolerance 15 mins after glucose loading (2g/kg) when comparison to control mice 
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641 administered saline (solid black line circle icon). No difference in glucose tolerance was seen 
642 in mice administered AH (Antalarmin hydrochloride).  AUC from 0-30 min for each 
643 treatment group is displayed in panel B. No change in overall insulin sensitivity was observed 
644 between all treatment groups (C). AUC from 0-60min for each treatment group is displayed 
645 in panel D, (n=7-19). In non-pregnant mice chronic administration of α-helical CRF9-41 had 
646 no significant effects on glucose tolerance (E) or insulin sensitivity (G). AUC for glucose 
647 tolerance 0-30 min and insulin sensitivity 0-60 min are displayed in panel F and H 
648 respectively, (n=5-6). Data are presented as mean ± S.E.M., # (Control vs α-helical CRF9-41) / 
649 * (Control vs AS-30): 15 mins p<0.05; Two-way repeated measures ANOVA followed by 
650 Tukey’s multiple comparisons test.
651
652 Figure. 5: Effect of chronic administration of a non-selective CRHR antagonist (α-helical 
653 CRF 9-41) on β-cell morphology during pregnancy. Representative images of immunostaining 
654 for the measurement of β-cell proliferation in control (A) and α-helical CRF 9-41 (B) islets 
655 showing insulin staining (red) and BrdU staining (green). Mice administered BrdU from days 
656 14 – 18 of pregnancy displayed no significant differences in the percentage of BrdU labelled 
657 β-cells between control and α-helical CRF 9-41 treated mice (C). Average β-cell size (D) and 
658 average β-cell islet area (E) were also unchanged between control and antagonist treatments. 
659 Data presented showing quantification (3-4 sections/animal analysed) for individual animals 
660 with bar showing mean, n=8-9 animals per treatment group. Scale bar- 50 μm
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